AlloEx
Phase 1Cell therapy
AlloEx is one of 57 biologic programs targeting Trigeminal Neuralgia. It is currently in Phase 1.
3
Indications
5
Total Trials
4
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Activase
RochePreclinical
Zometa
PfizerPreclinical
Savella
AbbViePreclinical
Folvite
Eli LillyPreclinical
Repatha
AmgenPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Zantac 150
CChattem
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Congenital Myasthenic Syndrome1 trial
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT07226726·20 enrolled
Motor Disorders1 trial
Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution
Completed·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT07105371·18 enrolled
Trigeminal Neuralgia1 trial
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells Exosomes for Trigeminal Neuralgia
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05152368·20 enrolled
Mesenchymal Stem Cell1 trial
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosomes for Parkinson's Disease
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05152394·20 enrolled
Stroke1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AlloEx. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details